



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville, MD 20857

NDA 17-670/S-043

Abbott Laboratories  
D-389, Bldg. J45-2  
200 Abbott Park Road  
Abbott Park, Illinois 60064

Attention: Jeremy Rybicki  
Specialist, Regulatory Affairs

Dear Mr. Rybicki:

Please refer to your supplemental new drug application dated July 31, 1998, received August 4, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for 0.45%, and 0.9% Sodium Chloride Irrigation Solution in Semi-Rigid Container.

We acknowledge the receipt of your submission dated October 20, 2003, which constituted a complete response to our August 21, 2002, action letter.

This supplemental new drug application provides for a revised **PRECAUTIONS** section. A **Geriatric Use** subsection is added in accordance with 21 CFR 201.57(f)(10).

We have completed our review of this application as amended, and it is approved effective on the date of this letter.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Pratibha Rana, Regulatory Project Manager, at (301) 827-7431.

Sincerely,

*{See appended electronic signature page}*

Bob A. Rappaport, M.D.  
Director  
Division of Anesthetic, Critical Care,  
and Addiction Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bob Rappaport  
4/7/04 04:56:11 PM